The coagulopathy in sepsis: significance and implications for treatment

• Main Authors: Berardino Pollio, Mauro Pagliarino, Carlo Scolfaro, Paola Saracco, Fabio Timeus, Pasquale Vitale
• Format: Article
• Language: English
• Published: MDPI AG 2011-09-01
• Series: Pediatric Reports
• Subjects: Sepsis, disseminated activated coagulation, coagulopathy, treatment
• Online Access: http://www.pagepress.org/journals/index.php/pr/article/view/3762

Sepsis related coagulopathy ranges from mild laboratory alterations up to severe disseminated intravascular coagulation (DIC). There is evidence that DIC is involved in the pathogenesis of microvascular dysfunction contributing to organ failure. Additionally, the systemic activation of coagulation, by consuming platelets and coagulation factors, may cause bleeding. Thrombin generation via the tissue factor/factor VIIa route, contemporary depression of antithrombin and protein C anticoagulant system, as well as impaired fibrin degradation, due to high circulating levels of PAI-1, contribute to enhanced intravascular fibrin deposition. This deranged coagulopathy is an independent predictor of clinical outcome in patients with severe sepsis. Innovative supportive strategies aiming at the inhibition of coagulation activation comprise inhibition of tissue factor-mediated activation or restoration of physiological anticoagulant pathways, as the administration of recombinant human activated protein C or concentrate. In spite of some promising initial studies, additional trials are needed to define their clinical effectiveness in adults and children with severe sepsis.